CLRB Cellectar Biosciences Inc: Earnings per share for the last 12 months

The targeted oncology sector delivers explosive profit growth following product certification. The rolling period's annual change in net income per share reflects the asset's dynamics, where the current status is 66.10. Exclusive PDC patents guarantee business resilience, while the high qualification of the radiopharmaceutical staff, secured by stock option programs, minimizes the risk of losing key competencies under strict FDA oversight for Cellectar Biosciences (CLRB).

Cellectar (CLRB) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/15/2026

CLRB (Cellectar Biosciences Inc): analytical breakdowns and indicator data

- price and consensus price forecast:

Market Price Cellectar Biosciences Inc|CLRB - Price Target Chart

- company stock capitalization data:

Market Capitalization Cellectar|CLRB - Enterprise Value

- book capitalization indicators:

Accounting Value per Share Cellectar Biosciences|CLRB - Company Book Value|Market-to-Book Ratio cellectar.com|CLRB - Aggregate Company Assets

- company total debt and liquidity indicators:

- earnings and market multiples details:

CLRB - Net Income|Future Net Profit Cellectar Biosciences|CLRB - P/E Multiple|Future Price to Earnings Multiple Cellectar|CLRB - PEG Multiple|Company Value to EBITDA Cellectar Corp|CLRB - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Cellectar Biosciences|CLRB - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth cellectar.com|CLRB - Earnings per share growth in current year|Net earnings per share change forecast for next year Cellectar Biosciences

- revenue and sales details:

CLRB - Company Sales|Company Expected Sales Volume Cellectar Biosciences, Inc.|CLRB - P/S Multiple|Forward Price-to-Revenue Multiple Cellectar

Fundamental company valuation:CLRB Cellectar

Flagship merchandise of Cellectar Biosciences, Inc.

For Cellectar Biosciences (CLRB), which is currently in the pre-commercial stage of radiopharmaceutical development, investment potential is driven by the anticipation of NDA approval rather than current cash flow. By analyzing the annual EPS TTM YoY trend, an investor assesses the rate of change in net income per share over twelve months, allowing for the differentiation of actual business scaling from rising operating expenses to determine the final cost of capital.

Direct competitors